However, we speculate that if there is an IL-4 > nTh1 > IFN-γ axis in diseases such as allergic asthma, attempts to reduce IL-4 using monoclonal antibody approaches (such as in pascolizumab46), may disrupt a homeostatic network that may have unknown consequences. The gene discussed is NTHL1; the disease is allergic asthma.